Dolutegravir News
Dolutegravir currently has 2 news articles, with 20 predicted indications.
This page combines the AI-predicted indications for Dolutegravir with the latest health news. Indications highlighted in orange have recent news coverage.
Drug Information
- Original indication: Tivicay is indicated in combination with other anti-retroviral medicinal products for the treatment of Human Immunodeficiency Virus (HIV) infected adults, adolescents and children of at least 6 years...
- Evidence level: L5
- Predicted indications (20):
- HIV infectious disease (99.9%)
- feline acquired immunodeficiency syndrome (99.8%)
- simian immunodeficiency virus infection (99.8%)
- neurodevelopmental disorder with ataxic gait, absent speech, and decreased cortical white matter (99.8%)
- AIDS (98.1%)
- chronic hepatitis C virus infection (96.4%)
- congenital human immunodeficiency virus (96.4%)
- AIDS related complex (96.4%)
- hepatitis C virus infection (93.7%)
- obsolete familial combined hyperlipidemia (93.4%)
- hepatitis E virus infection (92.5%)
- hepatitis A virus infection (92.3%)
- Omsk hemorrhagic fever (92.2%)
- hepatitis, viral, animal (92.0%)
- Kyasanur forest disease (92.0%)
- fibroma of prostate (92.0%)
- Brenner tumor (91.8%)
- benign reproductive system neoplasm (91.7%)
- benign prostate phyllodes tumor (91.4%)
- hepatitis B virus infection (91.2%)
Related News (2)
Controversial vaccine trial touted by RFK Jr gets go-ahead in Guinea-Bissau - The Guardian
2026-10-09 hepatitis
Source: The Guardian
Meteo estremo, cibo contaminato, ricoveri lunghi. A Roma è boom di Epatite A: perché c’è da preoccuparsi
2026-10-08 epatite
Source: RomaToday
Disclaimer: The news on this page is collected automatically and is for research reference only; it does not constitute medical advice.